Home Hemodialysis With NxStage System One Can Save California 221 Million Gallons of Water Annually
Data shows significant water conservation possible with NxStage's small, portable, easy-to-use home hemodialysis machine
LAWRENCE, Mass., June 3, 2015 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of dialysis products, today announced data that home hemodialysis can save California 221 million gallons of water annually by transitioning just 20 percent of its in-center dialysis patients to home hemodialysis with the NxStage® System One™. Industry data shows conventional in-center dialysis uses approximately 429 gallons of water per patient per week, whereas home hemodialysis with the NxStage System One uses only 30 gallons of water per patient per week.
The above infographic illustrates the dramatic impact home hemodialysis with the System One can have on water consumption in the state of California.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis and home nocturnal hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. http://www.nxstage.com/.
About NxStage Medical
NxStage Medical Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2015. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
[email protected]
Tel: (978) 332-5923
Photo - http://photos.prnewswire.com/prnh/20150603/220510-INFO
Logo - http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
SOURCE NxStage Medical, Inc.
Share this article